Top Healthcare and Biotech Focused Hedge Funds Surge; Oversee $70 Billion in Equity Assets

April 20th, 2014
| More
The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $70 billion in U.S. equity assets. Larry Robbins’ Glenview Capital Management has retained the top spot, once again, with $13.2 billion in equity assets under management. Glenview Capital’s sector favorites include Thermo Fisher Scientific (TMO), HCA Holdings Inc (HCA) and Health Management Associates (HMA). Over the last quarter, Glenview Capital notably increased its bets on Tenet Healthcare (THC) and Aetna Inc (AET).

Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #2 OrbiMed Advisors, #3 Baker Bros. Advisors LLC, and #4 Partner Fund Management. The largest investments for OrbiMed Advisors, which is run by industry stalwart Samuel Isaly, include Gilead Sciences Inc (GILD), Biogen Idec Inc (BIIB) and Bristol-Myers Squibb (BMY). Notably, Isaly’s firm entered and bought up large stakes in Relypsa Inc (RLYP), Perrigo Co (PRGO) and Acceleron Pharma (XLRN) over the quarter, while also increasing its stakes in Abbvie Inc (ABBV) and Celgene Corp (CELG).

Baker Bros. Advisors’ top positions include Pharmacyclics Inc (PCYC), Seattle Genetics (SGEN) and Incyte Corp (INCY), while Partner Fund Management’s top industry picks include Gilead Sciences Inc (GILD), Bristol-Myers Squibb (BMY) and Actavis Inc (ACT).

Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below:
Glenview Capital Management
OrbiMed Advisors
Partner Fund Management
Related People: Brian Grossman; Christopher Aristides; Christopher James; Larry Robbins; Samuel Isaly
Related Entities: Caduceus Asia Partners LP; Caduceus Capital LP; Eaton Vance Worldwide Health Sciences; Finsbury Worldwide Pharmaceutical; GCM Little Arbor Institutional Partners; GCM Little Arbor Master; GCM Little Arbor Partners; Glenview Capital Master; Glenview Capital Partners; Glenview Institutional Partners; OrbiMed Associates; OrbiMed Capital; Partner Fund; Partner Healthcare Fund; Partner Principal Fund; Partner Technology Fund; PFM Meritage
Related Article Tags: Multi-Strategy, Long Short, Equity, Debt and Global Macro Hedge Fund News; Top Hedge Fund Portfolio Reports


More Recent Headlines

Third Point’s Daniel Loeb Taking the Fight to Sotheby’s Board in Annual Meeting Showdown

Investor interest in Event-Driven hedge funds draws Magnetar Capital veterans to launch Anandar Capital Management

Top Connecticut Hedge Funds Surge; Assets up by 7.6%

Tiger Global Management leads $80 Million Funding Round for Quora Inc

Dymon Asia Capital partners with SAC Capital veteran Carl Vine to launch Port Meadow Hedge Fund

Top 50 California Hedge Funds up more than 10% for the quarter; ValueAct Capital and SPO Advisory still on top

Top Technology, Media & Telecom Hedge Funds Report $130B; Philippe Laffont’s Coatue Capital maintains top spot

Top Hedge Funds jump to $875 billion mark, up 13% for the quarter to finish 2013 strong

Assets of Top 200 New York Metro Area Hedge Funds surge 12% in latest HedgeTracker list

Top Emerging Hedge Fund Managers for 2014 Revealed; PointState Capital, Soroban Capital and Corvex Management lead the way